Polycystic Ovary Syndrome

• Insulin Resistance and Hyperinsulinemia as Central Feature: Approximately 70% of women with PCOS demonstrate insulin resistance independent of body weight or glucose intolerance status. This resistance occurs at the level of the insulin receptor and post-receptor signaling (particularly affecting phosphatidylinositol 3-kinase [PI3K] pathway) in skeletal muscle and hepatic tissue. Compensatory hyperinsulinemia develops to maintain glucose homeostasis. Elevated fasting insulin levels (>12 mIU/L) and abnormal insulin tolerance testing are hallmark findings. Hyperinsulinemia directly stimulates ovarian theca cells to increase androgen production through enhanced activity of 17α-hydroxylase/17,20-lyase (CYP17A1 enzyme complex), bypassing normal negative feedback mechanisms. This creates a self-perpetuating cycle of androgen excess and metabolic dysfunction.

• Abnormal Androgen Biosynthesis and Altered Luteinizing Hormone (LH) Signaling: The hypothalamic-pituitary axis exhibits exaggerated responsiveness in PCOS, with elevated basal LH levels and increased LH pulse frequency and amplitude. The LH:FSH ratio is typically elevated (often >2:1 or 3:1), though this is neither sensitive nor specific for diagnosis. Increased LH directly stimulates theca cell androgen production (particularly androstenedione and testosterone) and inhibits aromatase activity in granulosa cells, reducing local estradiol production. Elevated intra-ovarian androgens arrest follicle development at the pre-antral and early antral stages, preventing the rise in FSH needed for final maturation and ovulation. Women with PCOS also demonstrate altered 17-hydroxyprogesterone responses to GnRH stimulation, suggesting intrinsic abnormalities in ovarian steroidogenesis beyond simple substrate availability. Additionally, adrenal androgens may be elevated in 20–30% of PCOS patients, with elevated 17-hydroxyprogesterone suggesting mild adrenal hyperresponsiveness to ACTH.

• Follicle Development Arrest and Anovulation: The fundamental ovarian pathology results from disrupted folliculogenesis. While ovaries contain excessive numbers of primordial and small growing follicles (not true "cysts" but rather follicles arrested at the 5–8 mm stage), the arrest prevents recruitment of dominant follicles and formation of the corpus luteum. The mechanism involves both elevated intra-ovarian androgens (which are toxic to developing oocytes at high concentrations) and dysregulation of local growth factors including abnormal AMH (anti-müllerian hormone) secretion. AMH levels are 2–4 fold higher in PCOS, correlating with follicle number and reflecting increased numbers of small antral follicles. This arrest of follicle development eliminates the progressive rise in FSH that normally triggers the LH surge, resulting in chronic anovulation. Importantly, ovulation may occur sporadically in some PCOS patients, explaining why pregnancy can occur without intervention, though infertility rates remain high at 30–40%.

• Abnormal Adipokine Signaling and Chronic Inflammation: Beyond insulin resistance, PCOS involves dysregulation of adipose tissue-derived signals. Women with PCOS demonstrate elevated circulating levels of inflammatory cytokines (TNF-α, IL-6, IL-18) and reduced adiponectin levels. Low adiponectin impairs insulin sensitivity and is associated with increased cardiovascular risk. This chronic low-grade inflammatory state may contribute to both metabolic dysfunction and reproductive abnormalities. Macrophage infiltration into ovarian tissue has been documented, suggesting local inflammatory processes within the ovary itself that may contribute to impaired folliculogenesis and altered steroidogenesis.

• Abnormalities in AMH (Anti-Müllerian Hormone) and Ovarian Reserve: Despite elevated ovarian androgen production and increased follicle number, women with PCOS do not experience accelerated oocyte depletion. However, AMH levels are characteristically elevated (often 2–4 times higher than controls with similar age and BMI), reflecting increased granulosa cell secretion from the excess small antral follicles. Elevated AMH may paradoxically impair FSH signaling, contributing to the arrest of follicle development. Interestingly, although PCOS is associated with elevated follicle numbers, oocyte quality may be compromised, contributing to higher miscarriage rates independent of age.

• Genetic and Epigenetic Contributions: PCOS demonstrates complex inheritance with significant heritability (estimated 70–80% in some studies), though no single causative gene has been identified. Genome-wide association studies (GWAS) have identified multiple susceptibility loci associated with PCOS, including genes involved in insulin signaling, follicle development, and gonadotropin signaling (THADA, DENND1A, YAP1, and others). Intrauterine androgen exposure during fetal development may predispose to PCOS phenotype, supported by animal models showing that prenatal androgen exposure produces PCOS-like features. Epigenetic modifications (DNA methylation, histone modifications) affecting genes involved in metabolic and reproductive function have been documented in PCOS and may contribute to disease expression.

• Genetic Predisposition with Environmental Modulation: Multiple genetic variants increase PCOS susceptibility, though gene-environment interactions are critical for phenotypic expression. Family history of PCOS is present in 20–40% of affected women. Intrauterine exposure to excess androgens (from maternal virilization during pregnancy or from fetal ovarian androgen production) may imprint the PCOS phenotype. Postnatal obesity significantly amplifies insulin resistance and clinical manifestations, suggesting that environmental factors critically influence whether genetic predisposition manifests as clinical disease.

• Obesity and Weight Gain: While PCOS occurs in lean individuals (10–20% of cases), obesity significantly exacerbates insulin resistance and androgen excess. Weight gain is associated with worsening of PCOS features, while weight loss (even 5–10% of body weight) improves metabolic parameters and ovulatory function. Abdominal (visceral) obesity correlates more strongly with insulin resistance and metabolic complications than overall BMI in PCOS.

• Prenatal Exposure Factors: Prenatal androgen exposure is hypothesized as a critical developmental programming factor. Animal models demonstrate that prenatal androgen excess produces PCOS-like features including polycystic ovaries, anovulation, and metabolic dysfunction. Maternal nutritional factors, particularly those affecting insulin metabolism in utero, may also influence PCOS development.

• Differential Diagnosis—Secondary Hyperandrogenism to Exclude: Before diagnosing PCOS, secondary causes of hyperandrogenism and anovulation must be excluded. These include: androgen-secreting tumors (ovarian or adrenal), Cushing syndrome, thyroid dysfunction, congenital adrenal hyperplasia (21-hydroxylase deficiency most common), and acromegaly. The diagnosis of PCOS requires exclusion of these secondary causes.

• Irregular Menstrual Cycles and Amenorrhea: The most common reproductive complaint, occurring in 80% of PCOS patients. Women typically present with either oligomenorrhea (cycles >35 days or <8 cycles per year) or amenorrhea. The pattern reflects anovulation and failure of normal luteal phase progesterone production, which normally provides negative feedback to suppress LH. Irregular cycles often begin at menarche (reflecting early manifestation of the disorder) but may worsen with age, weight gain, or metabolic deterioration. Some women experience polymenorrhea (frequent, light periods) from breakthrough bleeding associated with unopposed estrogen stimulation of the endometrium without progesterone opposition.

• Infertility and Anovulatory Cycles: Occurs in 30–40% of PCOS patients attempting conception. Even in women with relatively regular cycles, ovulation may be sporadic or absent. The pathophysiology relates to arrested follicle development preventing the normal preovulatory LH surge. When conception does occur, miscarriage rates are elevated (30–50% compared to 15–20% in general population), attributed to impaired endometrial development, elevated androgens, and possible oocyte dysfunction. Notably, PCOS represents the most common cause of anovulatory infertility.

• Hirsutism (Excessive Hair Growth): Reported in 60–80% of PCOS patients. Hirsutism represents androgen-dependent hair growth in a male-pattern distribution (face, chest, abdomen, upper back, inner thighs) resulting from increased circulating androgens and/or increased skin 5α-reductase activity converting testosterone to dihydrotestosterone. Severity correlates incompletely with androgen levels, reflecting variable skin sensitivity. Quantified using the Ferriman-Gallwey score (score ≥8 indicates hirsutism; normal varies by ethnicity). The psychological impact is significant, contributing to reduced quality of life and self-esteem.

• Acne and Male-Pattern Baldness (Androgenetic Alopecia): Acne occurs in 20–25% of PCOS patients and may persist into adulthood (distinguishing it from typical adolescent acne that resolves by early 20s). Acne reflects sebaceous gland stimulation by elevated androgens and is often resistant to topical treatment alone, requiring systemic therapy. Male-pattern hair loss (androgenetic alopecia) occurs in 30% of women with PCOS, manifesting as vertex thinning and widening of the central scalp part. These features often cause significant psychological distress.

• Obesity and Weight Distribution Abnormalities: Obesity is present in 30–50% of PCOS patients, though lean PCOS phenotypes occur. Weight gain in PCOS often shows central/abdominal predominance (visceral adiposity), which correlates more strongly with metabolic dysfunction than overall BMI. Women with PCOS frequently report difficulty with weight loss despite caloric restriction, partly due to underlying insulin resistance.

• Metabolic Manifestations: Insulin resistance and related metabolic abnormalities are present in up to 70% of PCOS patients. These may manifest as acanthosis nigricans (dark velvety skin thickening typically at neck, axillae, inframammary areas), reflecting severe insulin resistance. Dyslipidemia is common with elevated triglycerides and low HDL cholesterol. Impaired fasting glucose (100–125 mg/dL) or overt type 2 diabetes mellitus develops in 30–40% of PCOS women, with significantly elevated risk compared to age/BMI-matched controls.

• Cardiovascular Symptoms: Many PCOS women report fatigue, reduced exercise tolerance, and dyspnea on exertion related to metabolic dysfunction and increased cardiovascular risk factors. However, most cardiovascular manifestations are subclinical until complications develop.

• Physical Examination Findings: Beyond hirsutism, acne, and alopecia, examination may reveal obesity with central fat distribution, acanthosis nigricans, and skin tags (reflecting severe insulin resistance). Ovarian enlargement is not typically appreciated on pelvic examination as ovaries in PCOS are usually small or normal-sized (despite appearing enlarged on ultrasound due to increased follicle number). Pelvic examination findings are often normal.

• Clinical Variants and Heterogeneity: PCOS demonstrates significant phenotypic heterogeneity based on diagnostic criteria applied. Four distinct phenotypes are recognized: (1) hyperandrogenic/ovulatory PCOS (elevated androgens + polycystic ovaries, regular cycles); (2) hyperandrogenic/anovulatory PCOS (the "classic" phenotype with elevated androgens + anovulation + polycystic ovaries); (3) lean PCOS (normal weight, otherwise typical features); and (4) normoandrogenic PCOS (normal androgen levels but anovulation and/or polycystic ovaries). Each phenotype carries different metabolic and reproductive implications.

• Rotterdam Diagnostic Criteria (2003)—Most Widely Used: Diagnosis requires 2 of 3 major criteria: (1) oligo- or anovulation; (2) clinical and/or biochemical hyperandrogenism; and (3) polycystic ovarian morphology on imaging (after exclusion of secondary causes). The Rotterdam criteria have increased sensitivity compared to older NIH criteria but lower specificity. These criteria identify four distinct phenotypes noted above, each with different metabolic and reproductive implications.

• Historical Diagnostic Criteria (NIH 1990): Required hyperandrogenism (clinical or biochemical) plus anovulation plus exclusion of secondary causes. These older criteria do not specifically require polycystic ovarian morphology and identify only the most severe (hyperandrogenic/anovulatory) phenotype. They remain important for research and allow identification of more clearly affected individuals.

• Biochemical Assessment of Androgen Status: Total testosterone (elevated >55 ng/dL or 1.9 nmol/L suggests hyperandrogenism; normal postmenopausal <40 ng/dL) and free testosterone (elevated >4.3 pg/mL or 0.15 nmol/L) are the most specific markers of ovarian androgen excess in PCOS. Radioimmunoassay or liquid chromatography-mass spectrometry (LC-MS) should be used rather than immunoassay for accurate free testosterone measurement. Elevated testosterone may fluctuate with ovulatory cycles, so multiple measurements may be needed if initial testing is borderline. Androstenedione and DHEA-S (dehydroepiandrosterone sulfate) are also typically elevated, with androstenedione >3 ng/mL suggesting ovarian source. Critically, 17-hydroxyprogesterone should be measured to exclude 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH), which presents identically to PCOS. Values <2 ng/mL generally exclude CAH, though some advocate for ACTH stimulation testing if CAH is suspected clinically.

• LH, FSH, and LH:FSH Ratio: Basal LH is typically elevated (>10–15 mIU/L; upper limit of normal varies by assay) or at the upper limit of normal. FSH is usually low-normal (3–5 mIU/L). The LH:FSH ratio is often elevated (≥2:1 to 3:1), though this is neither sensitive nor specific for diagnosis and should not be used as a sole diagnostic criterion. Many normal women may have elevated ratios, and some PCOS patients have normal ratios. These measurements are less commonly used for diagnosis now but remain helpful as supportive findings.

• Metabolic Assessment: Fasting glucose and 2-hour glucose on 75-g oral glucose tolerance test (OGTT) should be obtained to screen for impaired fasting glucose, impaired glucose tolerance, or overt diabetes. Fasting insulin level >12 mIU/L suggests insulin resistance. Homeostatic model assessment of insulin resistance (HOMA-IR) is calculated as [fasting glucose (mg/dL) × fasting insulin (mIU/L)]/405, with values >2 indicating significant insulin resistance (though cutoff varies by population). Lipid panel including total cholesterol, LDL, HDL, and triglycerides is indicated to assess cardiovascular risk and identify dyslipidemia typical in PCOS (elevated triglycerides, low HDL). Thyroid-stimulating hormone (TSH) should be measured to exclude hypothyroidism, which can mimic PCOS with oligomenorrhea and anovulation.

• Ovarian Imaging—Polycystic Ovarian Morphology: **Tran

Acute issues first

• Heavy anovulatory bleeding: unopposed-estrogen endometrium sloughs irregularly; stabilize with high-dose combined estrogen–progestin or IV conjugated estrogens, then transition to maintenance and biopsy if risk factors for hyperplasia exist.

Foundation for all patients

• Lifestyle modification: 5–10% weight loss lowers insulin and SHBG-bound-free androgen, often restoring ovulation; recommended first regardless of phenotype.

Not pursuing pregnancy — first line

• Combined hormonal contraceptives (e.g., a low-dose estrogen–progestin pill): suppress LH-driven theca androgen output, raise SHBG, and provide the progestin that protects the endometrium. First-line for both menstrual irregularity and hyperandrogenism.
• Antiandrogens: spironolactone, an androgen-receptor blocker, is added when hirsutism persists after roughly six months of a COC; always paired with reliable contraception because of feminization of a male fetus. Topical eflornithine and laser/mechanical hair removal are adjuncts.
• Metformin (biguanide): reduces hepatic gluconeogenesis and hyperinsulinemia; preferred when metabolic features, impaired glucose tolerance, or COC contraindications dominate. ADA Standards of Care support metformin in PCOS with prediabetes.
• Endometrial protection alternative: cyclic progestin or a levonorgestrel IUD when estrogen is contraindicated.

Pursuing pregnancy

• Letrozole (aromatase inhibitor) is first-line ovulation induction, superior to clomiphene for live birth in the PPCOS II trial.
• Clomiphene ± metformin, then gonadotropins or laparoscopic ovarian drilling second-line; IVF third-line.

Consequences of chronic anovulation

• Endometrial hyperplasia and endometrial carcinoma: unopposed estrogen without cyclic progestin drives continuous mitotic stimulation. Signals: prolonged amenorrhea followed by heavy or intermenstrual bleeding, thickened endometrial stripe. ACOG supports endometrial biopsy in women with PCOS and prolonged abnormal bleeding — this is the malignancy examiners test.
• Infertility and early pregnancy loss: arrested folliculogenesis; signals as failure to conceive despite regular intercourse.

Metabolic and cardiovascular sequelae

• Type 2 diabetes and metabolic syndrome: hyperinsulinemia with progressive beta-cell failure; signaled by abnormal 2-hour OGTT. ADA Standards of Care list PCOS as an indication for glycemic screening.
• Metabolic dysfunction–associated steatotic liver disease: hepatic lipogenesis from insulin resistance; signaled by transaminase elevation or hepatic steatosis on imaging.
• Obstructive sleep apnea and dyslipidemia (high triglycerides, low HDL) compound cardiovascular risk.

Treatment-related — flag the emergencies

• Ovarian hyperstimulation syndrome (EMERGENCY): VEGF-mediated capillary leak after gonadotropins or hCG trigger; ascites, hemoconcentration, oliguria, dyspnea, and thromboembolism. PCOS ovaries with high antral follicle counts are the highest-risk group.
• Multiple gestation: greater with gonadotropins than with letrozole or clomiphene.
• Venous thromboembolism (EMERGENCY): estrogen-induced procoagulant shift with combined contraceptives; unilateral leg swelling or pleuritic dyspnea.
• Hyperkalemia from spironolactone, especially with renal impairment or ACE inhibitors/ARBs.
• Metformin: gastrointestinal intolerance and vitamin B12 malabsorption; lactic acidosis is rare and largely confined to renal failure or hypoxic states.
• Laparoscopic ovarian drilling: adhesions and, rarely, diminished ovarian reserve.

• Rotterdam = 2 of 3: oligo-ovulation, hyperandrogenism, polycystic morphology — after exclusion of mimics. A stem with oligomenorrhea plus hirsutism needs no ultrasound to make the diagnosis.
• Letrozole is the single best next step for infertility: an aromatase inhibitor that lowers estrogen feedback and raises FSH. The classic distractor is clomiphene (now second-line) or metformin — metformin alone is not first-line ovulation induction.
• The association examiners love is endometrial carcinoma from unopposed estrogen. Any PCOS patient with prolonged amenorrhea then heavy bleeding → endometrial biopsy, not reassurance.
• Not seeking pregnancy → combined oral contraceptive first, with spironolactone added for persistent hirsutism only alongside contraception (feminization of a male fetus).
• Always check 17-hydroxyprogesterone to exclude nonclassic 21-hydroxylase deficiency, and TSH and prolactin for other causes of oligomenorrhea. Rapid virilization (clitoromegaly, voice deepening, over months) with markedly elevated testosterone or DHEA-S points to an androgen-secreting tumor — image the ovaries and adrenals rather than treating for PCOS.
• Buzzwords: acanthosis nigricans and skin tags = insulin resistance; Ferriman-Gallwey score ≥8 = hirsutism; "string of pearls" peripheral follicles on transvaginal ultrasound.
• LH:FSH ratio is a trap. It is supportive at best and is not part of the Rotterdam criteria; do not select it as the confirmatory test.
• Lifestyle is the answer more often than students expect: 5–10% weight loss can restore ovulation and is recommended for all phenotypes by the 2023 international PCOS guideline.
• In an IVF or gonadotropin stem, abdominal distention, ascites, and hemoconcentration = ovarian hyperstimulation syndrome, an emergency with thrombosis risk — PCOS is the top risk factor.